Transmigration of PBMNCs from β-IFN-1b-treated MS patients: A one-year longitudinal study

M. Gelati, E. Corsini, A. Dufour, M. Zaffaroni, C. Milanese, L. La Mantia, G. Massa, A. Salmaggi

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

To evaluate the effects of in vivo β-IFN-1b treatment on transmigration of mononuclear cells, we monitored for one year in vitro mononuclear cells trafficking through HUVECs monolayers stratified over a collagen gel during β-IFN-1b treatment of 7 RR MS patients. The number of transmigrated cells was analysed before treatment (T0) and after 3 (T3), 6 (T6) and 12 months (T12); at the same time, levels of serum MMP-9 were quantified. The number of transmigrated cells decreased during treatment compared to pre-treatment values: the lowest number of transmigrated cells was detected at T3, and, although transmigration was still lower at T12, there was a trend to a return to pre-treatment levels over time. The amount of MMP-9 also decreased during therapy, although we could not find an absolute correlation between transmigration and levels of MMP-9, nor between either parameter and the clinical course of patients.

Original languageEnglish
Pages (from-to)275-283
Number of pages9
JournalAutoimmunity
Volume33
Issue number4
Publication statusPublished - 2001

Fingerprint

Longitudinal Studies
Matrix Metalloproteinases
Cell Count
Therapeutics
Collagen
Gels
Serum

Keywords

  • β-IFN
  • MMP-9
  • Multiple sclerosis
  • Transmigration

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Gelati, M., Corsini, E., Dufour, A., Zaffaroni, M., Milanese, C., La Mantia, L., ... Salmaggi, A. (2001). Transmigration of PBMNCs from β-IFN-1b-treated MS patients: A one-year longitudinal study. Autoimmunity, 33(4), 275-283.

Transmigration of PBMNCs from β-IFN-1b-treated MS patients : A one-year longitudinal study. / Gelati, M.; Corsini, E.; Dufour, A.; Zaffaroni, M.; Milanese, C.; La Mantia, L.; Massa, G.; Salmaggi, A.

In: Autoimmunity, Vol. 33, No. 4, 2001, p. 275-283.

Research output: Contribution to journalArticle

Gelati, M, Corsini, E, Dufour, A, Zaffaroni, M, Milanese, C, La Mantia, L, Massa, G & Salmaggi, A 2001, 'Transmigration of PBMNCs from β-IFN-1b-treated MS patients: A one-year longitudinal study', Autoimmunity, vol. 33, no. 4, pp. 275-283.
Gelati, M. ; Corsini, E. ; Dufour, A. ; Zaffaroni, M. ; Milanese, C. ; La Mantia, L. ; Massa, G. ; Salmaggi, A. / Transmigration of PBMNCs from β-IFN-1b-treated MS patients : A one-year longitudinal study. In: Autoimmunity. 2001 ; Vol. 33, No. 4. pp. 275-283.
@article{fdfa0247913e462c8c9cbaa6bd7c1791,
title = "Transmigration of PBMNCs from β-IFN-1b-treated MS patients: A one-year longitudinal study",
abstract = "To evaluate the effects of in vivo β-IFN-1b treatment on transmigration of mononuclear cells, we monitored for one year in vitro mononuclear cells trafficking through HUVECs monolayers stratified over a collagen gel during β-IFN-1b treatment of 7 RR MS patients. The number of transmigrated cells was analysed before treatment (T0) and after 3 (T3), 6 (T6) and 12 months (T12); at the same time, levels of serum MMP-9 were quantified. The number of transmigrated cells decreased during treatment compared to pre-treatment values: the lowest number of transmigrated cells was detected at T3, and, although transmigration was still lower at T12, there was a trend to a return to pre-treatment levels over time. The amount of MMP-9 also decreased during therapy, although we could not find an absolute correlation between transmigration and levels of MMP-9, nor between either parameter and the clinical course of patients.",
keywords = "β-IFN, MMP-9, Multiple sclerosis, Transmigration",
author = "M. Gelati and E. Corsini and A. Dufour and M. Zaffaroni and C. Milanese and {La Mantia}, L. and G. Massa and A. Salmaggi",
year = "2001",
language = "English",
volume = "33",
pages = "275--283",
journal = "Autoimmunity",
issn = "0891-6934",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Transmigration of PBMNCs from β-IFN-1b-treated MS patients

T2 - A one-year longitudinal study

AU - Gelati, M.

AU - Corsini, E.

AU - Dufour, A.

AU - Zaffaroni, M.

AU - Milanese, C.

AU - La Mantia, L.

AU - Massa, G.

AU - Salmaggi, A.

PY - 2001

Y1 - 2001

N2 - To evaluate the effects of in vivo β-IFN-1b treatment on transmigration of mononuclear cells, we monitored for one year in vitro mononuclear cells trafficking through HUVECs monolayers stratified over a collagen gel during β-IFN-1b treatment of 7 RR MS patients. The number of transmigrated cells was analysed before treatment (T0) and after 3 (T3), 6 (T6) and 12 months (T12); at the same time, levels of serum MMP-9 were quantified. The number of transmigrated cells decreased during treatment compared to pre-treatment values: the lowest number of transmigrated cells was detected at T3, and, although transmigration was still lower at T12, there was a trend to a return to pre-treatment levels over time. The amount of MMP-9 also decreased during therapy, although we could not find an absolute correlation between transmigration and levels of MMP-9, nor between either parameter and the clinical course of patients.

AB - To evaluate the effects of in vivo β-IFN-1b treatment on transmigration of mononuclear cells, we monitored for one year in vitro mononuclear cells trafficking through HUVECs monolayers stratified over a collagen gel during β-IFN-1b treatment of 7 RR MS patients. The number of transmigrated cells was analysed before treatment (T0) and after 3 (T3), 6 (T6) and 12 months (T12); at the same time, levels of serum MMP-9 were quantified. The number of transmigrated cells decreased during treatment compared to pre-treatment values: the lowest number of transmigrated cells was detected at T3, and, although transmigration was still lower at T12, there was a trend to a return to pre-treatment levels over time. The amount of MMP-9 also decreased during therapy, although we could not find an absolute correlation between transmigration and levels of MMP-9, nor between either parameter and the clinical course of patients.

KW - β-IFN

KW - MMP-9

KW - Multiple sclerosis

KW - Transmigration

UR - http://www.scopus.com/inward/record.url?scp=0034847065&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034847065&partnerID=8YFLogxK

M3 - Article

C2 - 11683402

AN - SCOPUS:0034847065

VL - 33

SP - 275

EP - 283

JO - Autoimmunity

JF - Autoimmunity

SN - 0891-6934

IS - 4

ER -